• Medexus outlined a near-term growth strategy centered on U.S. commercialization of GRAFAPEX (treosulfan), an allo-HSCT conditioning regimen cleared by the FDA in January 2025.
• Fiscal year ended March 31, 2026 net revenue totaled USD 99.3 million; adjusted EBITDA was USD 16.5 million; operating cash flow was USD 18.9 million.
• GRAFAPEX generated USD 11.6 million in product-level net revenue; management targets USD 100 million+ within five years; adjusted gross margin pegged at 80%.
• U.S. sales drove 75% of net revenue; GRAFAPEX reached 64 U.S. institutions, or 36% of 180 transplant centers, with formulary wins and Medicare NTAP.
• Capital structure update showed net debt of USD 15.7 million; enterprise value of USD 108.9 million; shares outstanding of 32,000,000.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medexus Pharmaceuticals Inc. published the original content used to generate this news brief on July 20, 2026, and is solely responsible for the information contained therein.